Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment
Minchuan Zhang, Han Ping Loh, Shiyi Goh Fang, Yuansheng Yang, Kong-Peng Lam, Shengli Xu, Arash Hatefi · 2024
Read Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment by Minchuan Zhang, Han Ping Loh, Shiyi Goh Fang, Yuansheng Yang, Kong-Peng Lam, Shengli Xu, Arash Hatefi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11672634.txt.
Description
Minchuan Zhang and six colleagues design, published in 2024, molecules that steer natural killer cells onto myeloma cells. Myeloma is a cancer of plasma cells, and a surface marker called BCMA flags those cells. T-cell therapies against BCMA work well but can trigger dangerous overreaction, including cytokine storms and nerve damage. Killer cells from the innate immune system offer a calmer route. The team built bispecific engagers that grab BCMA on the tumor with one arm and CD16 on the killer cell with the other. A series of designs varied the format of that bridge.
In dish tests, the format changed how well the engagers worked. Geometry and valency of the bridge mattered, not just the two targets. The authors map those design effects for the next round of builders. Their goal is a myeloma therapy with T-cell power but without its worst side effects.
Catalog record
| CREATOR | Minchuan Zhang, Han Ping Loh, Shiyi Goh Fang, Yuansheng Yang, Kong-Peng Lam, Shengli Xu, Arash Hatefi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |